These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8464491)

  • 1. Properties of an HIV 'vaccine'.
    Wahren B; Sandström E; Wigzell H
    Nature; 1993 Apr; 362(6420):505; author reply 505-6. PubMed ID: 8464491
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine therapy using rgp 160 in early HIV infection.
    Redfield R; Birx D; Ketter N; Polonis V; Johnson S; Davis C; Smith G; Oster C; Burke D
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1333. PubMed ID: 1361350
    [No Abstract]   [Full Text] [Related]  

  • 4. Current progress in HIV vaccines.
    Westblom TU; Belshe RB; Gorse GJ
    Mo Med; 1991 Nov; 88(11):762-5. PubMed ID: 1805131
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccination with gp160 in HIV.
    Oyaizu N; Chirmule N; Pahwa S
    N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccination with gp160 in HIV.
    Stanberry LR; Bernstein DI; Myers MG
    N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748
    [No Abstract]   [Full Text] [Related]  

  • 7. AIDS vaccine boosts immunity in HIV patients.
    RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
    [No Abstract]   [Full Text] [Related]  

  • 8. Properties of an HIV 'vaccine'.
    Volvovitz F; Smith G
    Nature; 1993 Apr; 362(6420):504-5; author reply 505-6. PubMed ID: 8464490
    [No Abstract]   [Full Text] [Related]  

  • 9. Human trials of AIDS vaccines: current status and future directions.
    Koff WC; Fauci AS
    AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
    [No Abstract]   [Full Text] [Related]  

  • 10. MicroGeneSys drops out of NIH trial for AIDS vaccine.
    Macilwain C
    Nature; 1993 Mar; 362(6418):277. PubMed ID: 8455703
    [No Abstract]   [Full Text] [Related]  

  • 11. Two additional AIDS vaccines approved for clinical trials.
    J Am Osteopath Assoc; 1991 May; 91(5):433. PubMed ID: 2061098
    [No Abstract]   [Full Text] [Related]  

  • 12. Production in rabbits of high levels of anti-HIV-1 gp160 antibodies.
    Relyveld E; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):389-93. PubMed ID: 7580832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
    Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccine compromise.
    Nature; 1993 Apr; 362(6421):576. PubMed ID: 8464502
    [No Abstract]   [Full Text] [Related]  

  • 15. Which gp160 vaccine?
    Moore J; Lewis GK; Robinson J
    Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
    [No Abstract]   [Full Text] [Related]  

  • 16. [AIDS--HIV envelope protein improves vaccination response].
    GURTLER L
    Fortschr Med; 1991 Dec; 109(35):10-1. PubMed ID: 1774002
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
    Bona C; Nixon A; Kennedy R; Zaghouani H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1377. PubMed ID: 1466959
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunization of HIV-infected patients with rgp160: modulation of anti-rgp120 antibody spectrotype.
    Biselli R; Loomis LD; Del Bono V; Burke DS; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1016-24. PubMed ID: 8083819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody and cellular responses after HIV immunization.
    Wahren B
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 8051623
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiplatelet antibodies during the course of HIV-preventive vaccine trial.
    Kaplan C; Morel-Kopp MC; Kieny MP; Kolbe H; Salmon P; Sicard D; Pialoux G; Meignier B; Excler JL; Plotkin S
    AIDS; 1996 Apr; 10(4):447-9. PubMed ID: 8728055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.